Nothing Special   ยป   [go: up one dir, main page]

UA77408C2 - Metalloproteinase inhibitors, pharmaceutical composition on its base, and use thereof - Google Patents

Metalloproteinase inhibitors, pharmaceutical composition on its base, and use thereof Download PDF

Info

Publication number
UA77408C2
UA77408C2 UA2003098168A UA2003098168A UA77408C2 UA 77408 C2 UA77408 C2 UA 77408C2 UA 2003098168 A UA2003098168 A UA 2003098168A UA 2003098168 A UA2003098168 A UA 2003098168A UA 77408 C2 UA77408 C2 UA 77408C2
Authority
UA
Ukraine
Prior art keywords
group
alkyl
formula
compound
pharmaceutically acceptable
Prior art date
Application number
UA2003098168A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UA77408C2 publication Critical patent/UA77408C2/uk

Links

Classifications

    • Cโ€”CHEMISTRY; METALLURGY
    • C07โ€”ORGANIC CHEMISTRY
    • C07Dโ€”HETEROCYCLIC COMPOUNDS
    • C07D403/00โ€”Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02โ€”Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04โ€”Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Cโ€”CHEMISTRY; METALLURGY
    • C07โ€”ORGANIC CHEMISTRY
    • C07Dโ€”HETEROCYCLIC COMPOUNDS
    • C07D233/00โ€”Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54โ€”Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66โ€”Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72โ€”Two oxygen atoms, e.g. hydantoin
    • C07D233/76โ€”Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78โ€”Radicals substituted by oxygen atoms
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00โ€”Drugs for disorders of the alimentary tract or the digestive system
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00โ€”Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02โ€”Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00โ€”Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04โ€”Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00โ€”Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16โ€”Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00โ€”Drugs for disorders of the respiratory system
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00โ€”Drugs for disorders of the respiratory system
    • A61P11/02โ€”Nasal agents, e.g. decongestants
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00โ€”Drugs for disorders of the respiratory system
    • A61P11/06โ€”Antiasthmatics
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00โ€”Drugs for disorders of the urinary system
    • A61P13/12โ€”Drugs for disorders of the urinary system of the kidneys
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00โ€”Drugs for genital or sexual disorders; Contraceptives
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00โ€”Drugs for dermatological disorders
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00โ€”Drugs for dermatological disorders
    • A61P17/02โ€”Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00โ€”Drugs for dermatological disorders
    • A61P17/04โ€”Antipruritics
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00โ€”Drugs for dermatological disorders
    • A61P17/06โ€”Antipsoriatics
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00โ€”Drugs for skeletal disorders
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00โ€”Drugs for skeletal disorders
    • A61P19/02โ€”Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00โ€”Drugs for skeletal disorders
    • A61P19/04โ€”Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00โ€”Drugs for skeletal disorders
    • A61P19/06โ€”Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00โ€”Drugs for skeletal disorders
    • A61P19/08โ€”Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00โ€”Drugs for skeletal disorders
    • A61P19/08โ€”Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10โ€”Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00โ€”Drugs for disorders of the nervous system
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00โ€”Drugs for disorders of the nervous system
    • A61P25/02โ€”Drugs for disorders of the nervous system for peripheral neuropathies
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00โ€”Drugs for disorders of the nervous system
    • A61P25/28โ€”Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00โ€”Drugs for disorders of the senses
    • A61P27/02โ€”Ophthalmic agents
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00โ€”Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00โ€”Drugs for disorders of the metabolism
    • A61P3/08โ€”Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10โ€”Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00โ€”Antineoplastic agents
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00โ€”Antineoplastic agents
    • A61P35/04โ€”Antineoplastic agents specific for metastasis
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00โ€”Drugs for immunological or allergic disorders
    • A61P37/08โ€”Antiallergic agents
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00โ€”Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00โ€”Drugs for disorders of the blood or the extracellular fluid
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00โ€”Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02โ€”Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00โ€”Drugs for disorders of the cardiovascular system
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00โ€”Drugs for disorders of the cardiovascular system
    • A61P9/04โ€”Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • Aโ€”HUMAN NECESSITIES
    • A61โ€”MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Pโ€”SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00โ€”Drugs for disorders of the cardiovascular system
    • A61P9/10โ€”Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Cโ€”CHEMISTRY; METALLURGY
    • C07โ€”ORGANIC CHEMISTRY
    • C07Dโ€”HETEROCYCLIC COMPOUNDS
    • C07D233/00โ€”Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54โ€”Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66โ€”Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72โ€”Two oxygen atoms, e.g. hydantoin
    • C07D233/76โ€”Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • Cโ€”CHEMISTRY; METALLURGY
    • C07โ€”ORGANIC CHEMISTRY
    • C07Dโ€”HETEROCYCLIC COMPOUNDS
    • C07D401/00โ€”Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02โ€”Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12โ€”Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Cโ€”CHEMISTRY; METALLURGY
    • C07โ€”ORGANIC CHEMISTRY
    • C07Dโ€”HETEROCYCLIC COMPOUNDS
    • C07D401/00โ€”Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14โ€”Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Cโ€”CHEMISTRY; METALLURGY
    • C07โ€”ORGANIC CHEMISTRY
    • C07Dโ€”HETEROCYCLIC COMPOUNDS
    • C07D403/00โ€”Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02โ€”Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06โ€”Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Cโ€”CHEMISTRY; METALLURGY
    • C07โ€”ORGANIC CHEMISTRY
    • C07Dโ€”HETEROCYCLIC COMPOUNDS
    • C07D403/00โ€”Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02โ€”Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12โ€”Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Cโ€”CHEMISTRY; METALLURGY
    • C07โ€”ORGANIC CHEMISTRY
    • C07Dโ€”HETEROCYCLIC COMPOUNDS
    • C07D405/00โ€”Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02โ€”Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12โ€”Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Cโ€”CHEMISTRY; METALLURGY
    • C07โ€”ORGANIC CHEMISTRY
    • C07Dโ€”HETEROCYCLIC COMPOUNDS
    • C07D405/00โ€”Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14โ€”Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Cโ€”CHEMISTRY; METALLURGY
    • C07โ€”ORGANIC CHEMISTRY
    • C07Dโ€”HETEROCYCLIC COMPOUNDS
    • C07D409/00โ€”Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14โ€”Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • Cโ€”CHEMISTRY; METALLURGY
    • C07โ€”ORGANIC CHEMISTRY
    • C07Dโ€”HETEROCYCLIC COMPOUNDS
    • C07D417/00โ€”Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14โ€”Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Cโ€”CHEMISTRY; METALLURGY
    • C07โ€”ORGANIC CHEMISTRY
    • C07Dโ€”HETEROCYCLIC COMPOUNDS
    • C07D471/00โ€”Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02โ€”Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04โ€”Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
UA2003098168A 2001-03-15 2002-03-13 Metalloproteinase inhibitors, pharmaceutical composition on its base, and use thereof UA77408C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100902A SE0100902D0 (sv) 2001-03-15 2001-03-15 Compounds
PCT/SE2002/000478 WO2002074751A1 (fr) 2001-03-15 2002-03-13 Inhibiteurs des metalloproteinases

Publications (1)

Publication Number Publication Date
UA77408C2 true UA77408C2 (en) 2006-12-15

Family

ID=20283374

Family Applications (3)

Application Number Title Priority Date Filing Date
UA2003098168A UA77408C2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors, pharmaceutical composition on its base, and use thereof
UA2003098171A UA78502C2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors, use thereof, and pharmaceutical composition based thereon
UA2003098170A UA77667C2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors, pharmaceutical composition and use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
UA2003098171A UA78502C2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors, use thereof, and pharmaceutical composition based thereon
UA2003098170A UA77667C2 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors, pharmaceutical composition and use thereof

Country Status (33)

Country Link
US (8) US7427631B2 (fr)
EP (4) EP1370534A1 (fr)
JP (4) JP4390457B2 (fr)
KR (4) KR20030082986A (fr)
CN (5) CN101602731A (fr)
AR (2) AR035443A1 (fr)
AT (3) ATE493406T1 (fr)
AU (2) AU2002237626B2 (fr)
BR (3) BR0207984A (fr)
CA (3) CA2440473C (fr)
CY (1) CY1107525T1 (fr)
CZ (3) CZ20032499A3 (fr)
DE (3) DE60213216T2 (fr)
DK (1) DK1370556T3 (fr)
EE (3) EE05364B1 (fr)
ES (3) ES2267986T3 (fr)
HK (3) HK1091492A1 (fr)
HU (3) HUP0400194A3 (fr)
IL (5) IL157657A0 (fr)
IS (3) IS6943A (fr)
MX (3) MXPA03008191A (fr)
MY (2) MY136789A (fr)
NO (3) NO20034044L (fr)
NZ (3) NZ528106A (fr)
PL (3) PL205315B1 (fr)
PT (1) PT1370556E (fr)
RU (3) RU2285695C2 (fr)
SE (1) SE0100902D0 (fr)
SI (1) SI1370556T1 (fr)
SK (3) SK10952003A3 (fr)
UA (3) UA77408C2 (fr)
WO (3) WO2002074751A1 (fr)
ZA (4) ZA200306732B (fr)

Families Citing this family (66)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
JP2004535411A (ja) 2001-05-25 2004-11-25 ใƒ–ใƒชใ‚นใƒˆใƒซใƒผใƒžใ‚คใƒคใƒผใ‚บ ใ‚นใ‚ฏใ‚คใƒ– ใ‚ซใƒณใƒ‘ใƒ‹ใƒผ ใƒžใƒˆใƒชใƒƒใ‚ฏใ‚นใƒกใ‚ฟใƒญใƒ—ใƒญใƒ†ใƒŠใƒผใ‚ผๅŠใณ๏ผใพใŸใฏ๏ผด๏ผฎ๏ผฆโˆ’ฮฑ่ปขๆ›้…ต็ด ๏ผˆ๏ผด๏ผก๏ผฃ๏ผฅ๏ผ‰ใฎ้˜ปๅฎณๅ‰คใจใ—ใฆใฎใƒ’ใƒ€ใƒณใƒˆใ‚คใƒณๅŠใณ้–ข้€ฃ่ค‡็ด ็’ฐๅŒ–ๅˆ็‰ฉ
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0202693D0 (sv) * 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
EP1546109A4 (fr) * 2002-10-04 2005-11-09 Bristol Myers Squibb Co Derives d'hydantoine en tant qu'inhibiteurs de metalloproteinases matricielles et/ou de l'enzyme de conversion de tnf-alpha (tace)
JP4866610B2 (ja) 2003-08-18 2012-02-01 ๅฏŒๅฃซใƒ•ใ‚คใƒซใƒ ใƒ•ใ‚กใ‚คใƒณใ‚ฑใƒŸใ‚ซใƒซใ‚บๆ ชๅผไผš็คพ ใƒ”ใƒชใ‚ธใƒซใƒ†ใƒˆใƒฉใƒ’ใƒ‰ใƒญใƒ”ใƒชใ‚ธใƒณ้กžใŠใ‚ˆใณใƒ”ใƒชใ‚ธใƒซใƒ”ใƒšใƒชใ‚ธใƒณ้กž
US20050203156A1 (en) * 2004-03-12 2005-09-15 Wyeth Hydantoins having RNase modulatory activity
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
JP2008512463A (ja) * 2004-09-08 2008-04-24 ใƒœใƒผใ‚คใ‚บ ใ‚ฟใ‚ฆใƒณ ใƒŠใ‚ทใƒงใƒŠใƒซ ใƒชใ‚ตใƒผใƒ ใƒ›ใ‚นใƒ”ใ‚ฟใƒซ ใƒžใƒˆใƒชใƒƒใ‚ฏใ‚นใƒกใ‚ฟใƒญใƒ—ใƒญใƒ†ใ‚คใƒŠใƒผใ‚ผโˆ’๏ผ‘๏ผ’ใซ้–ข้€ฃใ™ใ‚‹็ณธ็ƒไฝ“ๅŸบๅบ•่†œ็–พๆ‚ฃใฎๆฒป็™‚
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP1830837B1 (fr) * 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Derives heterocycliques pour le traitement de maladies induites par des enzymes stearoyl-coadesaturases
JP5043668B2 (ja) 2004-09-20 2012-10-10 ใ‚ผใƒŽใƒณใƒปใƒ•ใ‚กใƒผใƒžใ‚ทใƒฅใƒผใƒ†ใ‚ฃใ‚ซใƒซใ‚บใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ่ค‡็ด ็’ฐ่ช˜ๅฐŽไฝ“ใŠใ‚ˆใณๆฒป็™‚่–ฌใจใ—ใฆใฎใใ‚Œใ‚‰ใฎไฝฟ็”จ
JP4958785B2 (ja) 2004-09-20 2012-06-20 ใ‚ผใƒŽใƒณใƒปใƒ•ใ‚กใƒผใƒžใ‚ทใƒฅใƒผใƒ†ใ‚ฃใ‚ซใƒซใ‚บใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ่ค‡็ด ็’ฐ่ช˜ๅฐŽไฝ“ใŠใ‚ˆใณใ‚นใƒ†ใ‚ขใƒญใ‚คใƒซโˆ’๏ผฃ๏ฝ๏ผกใƒ‡ใ‚ตใƒใƒฅใƒฉใƒผใ‚ผใ‚คใƒณใƒ’ใƒ“ใ‚ฟใƒผใจใ—ใฆใฎใใ‚Œใ‚‰ใฎไฝฟ็”จ
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibiรงรฃo de estearoil-coa-desaturase
EP2266569A3 (fr) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Dรฉrivรฉs hรฉtรฉrocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
JP2008513515A (ja) 2004-09-20 2008-05-01 ใ‚ผใƒŽใƒณใƒปใƒ•ใ‚กใƒผใƒžใ‚ทใƒฅใƒผใƒ†ใ‚ฃใ‚ซใƒซใ‚บใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ่ค‡็ด ็’ฐ่ช˜ๅฐŽไฝ“ใŠใ‚ˆใณๆฒป็™‚่–ฌใจใ—ใฆใฎใใ‚Œใ‚‰ใฎไฝฟ็”จ
GB0427403D0 (en) * 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
WO2006099598A2 (fr) * 2005-03-16 2006-09-21 Sensus Metering Systems Inc. Procede, systeme, appareil et programme informatique permettant de determiner un emplacement physique d'un capteur
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007078335A2 (fr) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Inhibiteurs de biaryl-azote-heterocycle de lta4h pour traiter l'inflammation
AR059036A1 (es) 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
TW200800954A (en) * 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200740769A (en) * 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
KR101293500B1 (ko) * 2006-05-12 2013-08-07 ์—์Šค์ฒด์•„ ํžˆ๊ธฐ์—๋„ˆ ํ”„๋กœ๋•์ธ  ์•…ํ‹ฐ์—๋ณผ๋ผ๊ทธ ์‹ ์ถ•์„ฑ ๋ผ๋ฏธ๋„ค์ดํŠธ ๋ฐ ์‹ ์ถ•์„ฑ ๋ผ๋ฏธ๋„ค์ดํŠธ ์ œ์กฐ ๋ฐฉ๋ฒ•
CA2650268A1 (fr) * 2006-05-12 2007-11-22 Sca Hygiene Products Ab Article absorbant de type culotte et procede de production d'articles absorbants de type culotte
WO2008053199A1 (fr) * 2006-10-30 2008-05-08 Astrazeneca Ab Thรฉrapie combinรฉe pour traiter des maladies respiratoire
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
WO2009007747A2 (fr) * 2007-07-11 2009-01-15 Astrazeneca Ab Nouveaux composรฉs
US20100262110A1 (en) 2007-11-14 2010-10-14 Sca Hygiene Products Ab Method of producing an absorbent garment, and an absorbent garment produced according to the method
US8303561B2 (en) 2007-11-14 2012-11-06 Sca Hygiene Products Ab Method of producing an absorbent garment, and an absorbent garment produced according to the method
FR2927330B1 (fr) * 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
BRPI0911612A2 (pt) 2008-04-28 2015-12-15 Revalesio Corp composiรงรตes e mรฉtodos para o tratamento da esclerose mรบltipla.
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
ES2525353T3 (es) * 2009-04-28 2014-12-22 Chugai Seiyaku Kabushiki Kaisha Derivado de espiroimidazolona
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011054734A1 (fr) * 2009-11-06 2011-05-12 Basf Se Catalyseur hรฉtรฉrogรจne contenant du fer et du manganรจse et procรฉdรฉ de fabrication d'olรฉfines par rรฉaction de monoxyde de carbone avec de l'hydrogรจne
WO2011061527A1 (fr) 2009-11-17 2011-05-26 Astrazeneca Ab Combinaisons qui comprennent un modulateur du rรฉcepteur glucocorticoรฏde, destinรฉes au traitement de maladies respiratoires
WO2011073662A1 (fr) 2009-12-17 2011-06-23 Astrazeneca Ab Association d'une benzoxazinone et d'un autre agent pour le traitement de maladies respiratoires
US20110202284A1 (en) * 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
KR20130087002A (ko) 2010-06-04 2013-08-05 ์•Œ๋ฐ”๋‹ˆ ๋ชฐ๋ ˆํ˜๋ผ ๋ฆฌ์จ์น˜, ์ธํฌ. ๊ธ€๋ฆฌ์‹  ์ˆ˜์†ก์ฒด-1 ์ €ํ•ด์ œ, ๊ทธ์˜ ์ œ์กฐ ๋ฐฉ๋ฒ• ๋ฐ ๊ทธ์˜ ์šฉ๋„
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
RU2639145C2 (ru) * 2012-09-04 2017-12-20 ะจะฐะฝั…ะฐะน ะฅัะฝะถัƒะน ะคะฐั€ะผะฐััŒัŽั‚ะธะบะฐะป ะšะพ., ะ›ั‚ะด. ะŸั€ะพะธะทะฒะพะดะฝั‹ะต ะพะบัะพั‚ะธะพะธะผะธะดะฐะทะพะปะธะดะธะฝะฐ, ัะฟะพัะพะฑั‹ ะธั… ะฟะพะปัƒั‡ะตะฝะธั ะธ ะธั… ะฟั€ะธะผะตะฝะตะฝะธะต ะฒ ะผะตะดะธั†ะธะฝะต ะฒ ะบะฐั‡ะตัั‚ะฒะต ะธะฝะณะธะฑะธั‚ะพั€ะพะฒ ะฐะฝะดั€ะพะณะตะฝะฝะพะณะพ ั€ะตั†ะตะฟั‚ะพั€ะฐ
MY178583A (en) 2012-12-10 2020-10-16 Chugai Pharmaceutical Co Ltd Hydantoin derivative
MX2016006147A (es) * 2013-11-13 2016-12-09 Hankkija Oy Suplemento alimenticio.
JP6227149B2 (ja) * 2013-12-31 2017-11-08 ใ‚คใƒ—ใ‚ปใƒณ ใƒ•ใ‚กใƒซใƒž ใ‚ฝใ‚ทใ‚จใƒ† ใƒ‘ใƒผใƒซ ใ‚ขใ‚ฏใ‚ทใ‚ชใƒณ ใ‚ตใƒณใƒ—ใƒชใƒ•ใ‚ฃใ‚จ๏ผฉ๏ฝ๏ฝ“๏ฝ…๏ฝŽ ๏ผฐ๏ฝˆ๏ฝ๏ฝ’๏ฝ๏ฝ ๏ผณ๏ผŽ๏ผก๏ผŽ๏ผณ๏ผŽ ๆ–ฐ่ฆใฎใ‚คใƒŸใƒ€ใ‚พใƒชใ‚ธใƒณโˆ’๏ผ’๏ผŒ๏ผ”โˆ’ใ‚ธใ‚ชใƒณ่ช˜ๅฐŽไฝ“
EP2907512A1 (fr) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibiteurs de MMP-12 en tant qu'agents antiviraux
CA2949023C (fr) 2014-06-09 2021-10-12 Hiroshi Noda Composition pharmaceutique contenant un derive d'hydantoine
KR102134171B1 (ko) 2014-10-24 2020-07-15 ๋ž€๋„์Šค ๋ฐ”์ด์˜คํŒŒ๋งˆ, ์ธํฌ. ๋ž€ํ‹ฐ์˜ค๋‹Œ ํ•ฉ์„ฑํšจ์†Œ c-์œ ์‚ฌ 2-๊ณ„ ์น˜๋ฃŒ์ œ
JO3501B1 (ar) 2014-12-22 2020-07-05 Servier Lab ู…ุดุชู‚ุงุช 5-{(ุจูŠุจุฑุงุฒูŠู† - 1-ูŠู„)-3-ุฃูˆูƒุณูˆ - ุจุฑูˆุจูŠู„}- ุฅูŠู…ูŠุฏุงุฒูˆู„ูŠุฏูŠู†-2ุŒ 4 - ุฏุงูŠูˆู† ูƒู…ุซุจุทุงุช ู„ adamts ู„ู…ุนุงู„ุฌุฉ ู‡ุดุงุดุฉ ุงู„ุนุธุงู…)
CN109803961B (zh) * 2016-09-23 2021-03-23 ็ง‘็ ”ๅˆถ่ฏๆ ชๅผไผš็คพ (r)-5-(3,4-ไบŒๆฐŸ่‹ฏๅŸบ)-5-[(3-็”ฒๅŸบ-2-ๆฐงไปฃๅกๅ•ถ-1(2h)-ๅŸบ)็”ฒๅŸบ]ๅ’ชๅ”‘็ƒท-2,4-ไบŒ้…ฎ็š„ๅˆถ้€ ๆ–นๆณ•ๅŠ็”จไบŽ่ฏฅๅˆถ้€ ็š„ไธญ้—ดไฝ“
WO2021011720A2 (fr) * 2019-07-18 2021-01-21 Avidence Therapeutics, Inc. Composรฉs anti-ostรฉoarthrite ainsi que compositions et mรฉthodes associรฉes
AU2020381485A1 (en) 2019-11-14 2022-06-16 Foresee Pharmaceuticals Usa, Inc. Matrix metalloproteinase (MMP) inhibitors and methods of use thereof
BR112022002387A2 (pt) 2019-12-20 2022-09-06 Landos Biopharma Inc Composto da fรณrmula z-y-q-y' ou um sal ou รฉster farmaceuticamente aceitรกvel do mesmo
EP4171553A1 (fr) 2020-06-26 2023-05-03 The University Of Birmingham Inhibition de mmp-9 et mmp-12 pour le traitement d'une lรฉsion de la moelle รฉpiniรจre ou d'une lรฉsion associรฉe ร  un tissu neurologique
WO2022007866A1 (fr) * 2020-07-09 2022-01-13 ๆทฑๅœณไฟก็ซ‹ๆณฐ่ฏไธš่‚กไปฝๆœ‰้™ๅ…ฌๅธ Dรฉrivรฉ tricyclique condensรฉ, son procรฉdรฉ de prรฉparation et son application pharmaceutique
CN112574193B (zh) * 2020-12-31 2022-05-17 ๅ—ไบฌๅŒป็ง‘ๅคงๅญฆ ไธ€็ฑปๅฃๆœgsnorๆŠ‘ๅˆถๅ‰‚ๅŠๅ…ถ่ฏ็‰ฉ็”จ้€”

Family Cites Families (94)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
US2327890A (en) * 1940-04-17 1943-08-24 Parke Davis & Co Substituted phenoxyalkyl ethers
US2745875A (en) * 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) * 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
CS152617B1 (fr) 1970-12-29 1974-02-22
CS151744B1 (fr) 1971-01-19 1973-11-19
US3849574A (en) 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) * 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS6172762A (ja) 1984-09-17 1986-04-14 Kanegafuchi Chem Ind Co Ltd ๅ…‰ๅญฆๆดปๆ€งใƒ’ใƒ€ใƒณใƒˆใ‚คใƒณ้กžใฎ่ฃฝ้€ ๆณ•
JPS61212292A (ja) * 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc ๏ผคโˆ’ฮฑโˆ’ใ‚ขใƒŸใƒŽ้…ธใฎ่ฃฝ้€ ๆ–นๆณ•
CA1325222C (fr) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Procede pour la production d'acide 4-biphenylylacetique
GB8618559D0 (en) 1986-07-30 1986-09-10 Genetics Int Inc Rhodococcus bacterium
JPH0279879A (ja) 1988-09-17 1990-03-20 Canon Inc ็”ปๅƒๅฝขๆˆ่ฃ…็ฝฎ
US4983771A (en) 1989-09-18 1991-01-08 Hexcel Corporation Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl) 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da) 1990-07-05 1990-07-05 Novo Nordisk As Fremgangsmaade til fremstilling af enantiomere forbindelser
IL99957A0 (en) 1990-11-13 1992-08-18 Merck & Co Inc Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoร„4,5-Bรœ-quinolin-2-one derivatives.
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
NL9201230A (nl) 1992-07-09 1994-02-01 Dsm Nv Werkwijze voor de bereiding van optisch aktief methionineamide.
EP0640594A1 (fr) 1993-08-23 1995-03-01 Fujirebio Inc. Dรฉrivรฉ de hydantoine comme inhibiteur de mรฉtalloprotease
JPH07105549A (ja) 1993-09-30 1995-04-21 Canon Inc ๅ…‰ๅญฆ็š„ๆƒ…ๅ ฑ่จ˜้Œฒๅ†็”Ÿๆ–นๆณ•ๅŠใณๅ…‰ๅญฆ็š„ๆƒ…ๅ ฑ่จ˜้Œฒๅ†็”Ÿ่ฃ…็ฝฎ
CA2174650A1 (fr) 1993-11-16 1995-05-26 Mark G. Bock Antagonistes piperidinylcamphresulfonyles de l'oxytocine
RU2126404C1 (ru) 1994-01-31 1999-02-20 ะŸั„ะฐะนะทะตั€ ะ˜ะฝะบ. 3r*, 4s* -3-[4-(4-ั„ั‚ะพั€ั„ะตะฝะธะป-4-ะณะธะดั€ะพะบัะธะฟะธะฟะตั€ะธะดะธะฝ-1-ะธะป] ั…ั€ะพะผะฐะฝ- 4,7-ะดะธะพะป, ะตะณะพ ะพะฟั‚ะธั‡ะตัะบะธะต ะธะทะพะผะตั€ั‹ ะธ ั„ะฐั€ะผะฐั†ะตะฒั‚ะธั‡ะตัะบะฐั ะบะพะผะฟะพะทะธั†ะธั ะฝะฐ ะตะณะพ ะพัะฝะพะฒะต ะธ ัะฟะพัะพะฑั‹ ะปะตั‡ะตะฝะธั
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
CZ291337B6 (cs) 1995-11-22 2003-02-12 Darwin Discovery Limited Merkaptoalkylpeptidylovรก slouฤenina, jejรญ pouลพitรญ pro vรฝrobu pล™รญpravku pro lรฉฤenรญ nebo prevenci stavu souvisejรญcรญho s metalloproteinรกzou nebo TNFalfa a farmaceutickรฝ pล™รญpravek ji obsahujรญcรญ
GB9616643D0 (en) 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1ฮฒ converting enzyme
WO1998017645A1 (fr) * 1996-10-22 1998-04-30 Pharmacia & Upjohn Company ACIDES ฮฑ-AMINO SULFONYLE HYDROXAMIQUES EN TANT QU'INHIBITEURS DE METALLOPROTEINASE DE MATRICE
EP0983239A1 (fr) 1997-05-06 2000-03-08 Novo Nordisk A/S Nouveaux composes heterocycliques
DK0877019T3 (da) 1997-05-09 2002-04-08 Hoechst Ag Substituerede diaminocarboxylsyrer
TR199903148T2 (xx) 1997-06-21 2000-04-21 Roche Diagnostics Gmbh Antimetastatik ve antit๏ฟฝm๏ฟฝr etkinli๏ฟฝi olan barbit๏ฟฝrik asit t๏ฟฝrevleri.
DE19726427A1 (de) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
ES2189207T3 (es) 1997-07-31 2003-07-01 Abbott Lab Inhibidores de hidroxamatos inversos de metaloproteinasas matriciales.
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
DK1030836T3 (da) * 1997-11-12 2003-05-26 Darwin Discovery Ltd Hydroxam- og carboxylsyrederivater der har MMP- og TNF-inhiberende aktivitet
BR9909322A (pt) 1998-02-04 2000-12-05 Novartis Ag Derivados de sulfonilamino que inibem metaloproteinases de degradaรงรฃo de matriz
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
EP1077974A1 (fr) 1998-05-14 2001-02-28 Du Pont Pharmaceuticals Company Acides hydroxamiques a substitution aryle en tant qu'inhibiteurs de metalloproteinase
CN1295561A (zh) 1998-06-03 2001-05-16 GpinilๆŽง่‚กๅ…ฌๅธ N๏ผๆ‚็Žฏ็พง้…ธๆˆ–็พง้…ธ็ญ‰ๆŽ’็‰ฉ็š„n๏ผ็ป“ๅˆๆฐจ็ฃบ้…ฐ
US6429213B1 (en) 1998-06-17 2002-08-06 Bristol Myers Squibb Pharma Co Cyclic hydroxamic acids as metalloproteinase inhibitors
FR2782082B3 (fr) 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
JP2000127349A (ja) * 1998-08-21 2000-05-09 Komori Corp ๅ‡น็‰ˆๅฐๅˆทๆฉŸ
WO2000012477A1 (fr) 1998-08-29 2000-03-09 British Biotech Pharmaceuticals Limited Derives d'acide hydroxamique comme inhibiteurs de proteinase
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
CA2346288A1 (fr) 1998-10-07 2000-04-13 Yazaki Corporation Procede sol-gel utilisant un moule poreux
ATE260255T1 (de) 1998-11-05 2004-03-15 Pfizer Prod Inc 5-oxo-pyrrolidine-2-carbonsรคure- hydroxamidderivate
BR9916363A (pt) 1998-12-18 2001-12-11 Axys Pharm Inc Composto, composiรงรฃo farmacรชutica e mรฉtodo paratratar ou prevenir um distรบrbio tromboembรณlico
WO2000040577A1 (fr) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. Derives de 1-carboxymethyl-2-oxo-azepan utilises comme inhibiteurs selectifs de mmp-12
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
CZ20012714A3 (cs) 1999-01-28 2002-08-14 Chugai Seiyaku Kabushiki Kaisha Substituovanรฉ derivรกty fenetylaminu
US6294694B1 (en) 1999-06-04 2001-09-25 Wisconsin Alumni Research Foundation Matrix metalloproteinase inhibitors and method of using same
GB9916562D0 (en) * 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
US20020006920A1 (en) 1999-07-22 2002-01-17 Robinson Ralph Pelton Arylsulfonylamino hydroxamic acid derivatives
US6266453B1 (en) 1999-07-26 2001-07-24 Computerized Medical Systems, Inc. Automated image fusion/alignment system and method
ES2258431T3 (es) 1999-08-02 2006-09-01 F. Hoffmann-La Roche Ag Proceso para la preparacion de derivados de benzotiofeno.
US7034049B1 (en) 1999-08-12 2006-04-25 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
JP3710964B2 (ja) 1999-08-26 2005-10-26 ๅฏŒๅฃซ้€šๆ ชๅผไผš็คพ ใƒ‡ใ‚ฃใ‚นใƒ—ใƒฌใ‚คใƒ‡ใƒใ‚คใ‚นใฎใƒฌใ‚คใ‚ขใ‚ฆใƒˆ่จญ่จˆๆ–นๆณ•
SE9904044D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
CA2419008A1 (fr) 2000-08-11 2003-02-11 Kaken Pharmaceutical Co., Ltd. Derives de l'acide 2,3-diphenylpropionique ou leurs sels, medicaments ou inhibiteurs d'adhesion cellulaire en contenant, et leur utilisation
US20020065219A1 (en) 2000-08-15 2002-05-30 Naidu B. Narasimhulu Water soluble thiazolyl peptide derivatives
WO2002020515A1 (fr) 2000-09-08 2002-03-14 Abbott Laboratories Agents antibacteriens a l'oxazolidinone
US20020091107A1 (en) * 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
EP1191024A1 (fr) 2000-09-22 2002-03-27 Harald Tschesche Thiadiazines et leur utilisation comme inhibiteurs de mรฉtalloproteinases
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US20040147573A1 (en) 2001-03-15 2004-07-29 Anders Eriksson Metalloproteinase inhibitors
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
JP2004535411A (ja) * 2001-05-25 2004-11-25 ใƒ–ใƒชใ‚นใƒˆใƒซใƒผใƒžใ‚คใƒคใƒผใ‚บ ใ‚นใ‚ฏใ‚คใƒ– ใ‚ซใƒณใƒ‘ใƒ‹ใƒผ ใƒžใƒˆใƒชใƒƒใ‚ฏใ‚นใƒกใ‚ฟใƒญใƒ—ใƒญใƒ†ใƒŠใƒผใ‚ผๅŠใณ๏ผใพใŸใฏ๏ผด๏ผฎ๏ผฆโˆ’ฮฑ่ปขๆ›้…ต็ด ๏ผˆ๏ผด๏ผก๏ผฃ๏ผฅ๏ผ‰ใฎ้˜ปๅฎณๅ‰คใจใ—ใฆใฎใƒ’ใƒ€ใƒณใƒˆใ‚คใƒณๅŠใณ้–ข้€ฃ่ค‡็ด ็’ฐๅŒ–ๅˆ็‰ฉ
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
CA2486350A1 (fr) 2002-06-05 2003-12-24 Kaneka Corporation Procede de production d'un derive .alpha.-methylcysteine optiquement actif
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0202693D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
SE0202692D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
GB0221250D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0221246D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US6890913B2 (en) * 2003-02-26 2005-05-10 Food Industry Research And Development Institute Chitosans
US20040266832A1 (en) 2003-06-26 2004-12-30 Li Zheng J. Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine
TWI220073B (en) * 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0401763D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200800954A (en) 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
JP2004523583A (ja) 2004-08-05
KR20030082986A (ko) 2003-10-23
EP1370556A1 (fr) 2003-12-17
KR20080071210A (ko) 2008-08-01
UA77667C2 (en) 2007-01-15
ES2267986T3 (es) 2007-03-16
NO20034042L (no) 2003-11-10
IL157656A0 (en) 2004-03-28
SK287766B6 (sk) 2011-09-05
CN1509286A (zh) 2004-06-30
US20080262045A1 (en) 2008-10-23
ZA200306737B (en) 2004-11-29
NZ528106A (en) 2005-03-24
IL157652A (en) 2010-11-30
AR035695A1 (es) 2004-06-23
IL157652A0 (en) 2004-03-28
IL157656A (en) 2010-11-30
JP5140058B2 (ja) 2013-02-06
ES2352246T3 (es) 2011-02-16
WO2002074767A1 (fr) 2002-09-26
CN1269804C (zh) 2006-08-16
ES2357138T3 (es) 2011-04-19
RU2285695C2 (ru) 2006-10-20
UA78502C2 (en) 2007-04-10
CA2440630C (fr) 2011-09-27
MXPA03008191A (es) 2004-01-29
HUP0400202A3 (en) 2004-10-28
HK1059932A1 (en) 2004-07-23
NO20034044L (no) 2003-11-10
IS6943A (is) 2003-09-09
SK10962003A3 (sk) 2004-03-02
CA2440630A1 (fr) 2002-09-26
CN1509272A (zh) 2004-06-30
US20040106659A1 (en) 2004-06-03
AU2002237626B2 (en) 2007-05-17
ZA200306732B (en) 2004-11-29
DE60238794D1 (de) 2011-02-10
EP1370537A1 (fr) 2003-12-17
JP2010077137A (ja) 2010-04-08
EP1676846B1 (fr) 2010-12-29
CN1304377C (zh) 2007-03-14
PL364707A1 (en) 2004-12-13
RU2003127733A (ru) 2005-03-20
EE05431B1 (et) 2011-06-15
NO20034045D0 (no) 2003-09-12
PL365099A1 (en) 2004-12-27
HUP0400327A2 (hu) 2005-01-28
EE05364B1 (et) 2010-12-15
ZA200306734B (en) 2004-11-29
EE200300449A (et) 2003-12-15
DE60237965D1 (en) 2010-11-25
NO20034044D0 (no) 2003-09-12
PL364706A1 (en) 2004-12-13
KR20030082989A (ko) 2003-10-23
BR0208104A (pt) 2004-03-02
SE0100902D0 (sv) 2001-03-15
HUP0400194A2 (hu) 2004-07-28
US7754750B2 (en) 2010-07-13
WO2002074748A8 (fr) 2004-04-22
US7666892B2 (en) 2010-02-23
CN1962641A (zh) 2007-05-16
EP1676846A3 (fr) 2006-07-26
SK10952003A3 (sk) 2004-05-04
ATE484496T1 (de) 2010-10-15
ZA200306731B (en) 2004-11-29
CY1107525T1 (el) 2013-03-13
MXPA03008177A (es) 2003-12-12
CA2440473A1 (fr) 2002-09-26
ATE493406T1 (de) 2011-01-15
US7625934B2 (en) 2009-12-01
EP1370537B1 (fr) 2010-10-13
BR0207983A (pt) 2004-06-15
NO20034045L (no) 2003-11-10
CN100526307C (zh) 2009-08-12
DE60213216T2 (de) 2007-07-12
IS6942A (is) 2003-09-09
KR100886315B1 (ko) 2009-03-04
US7427631B2 (en) 2008-09-23
MY136141A (en) 2008-08-29
CZ20032497A3 (cs) 2004-02-18
SI1370556T1 (sl) 2006-10-31
CA2440473C (fr) 2011-08-30
IL157657A0 (en) 2004-03-28
EE200300451A (et) 2003-12-15
EE200300445A (et) 2003-12-15
NO326087B1 (no) 2008-09-15
PT1370556E (pt) 2006-11-30
CZ20032499A3 (cs) 2004-03-17
US20040127528A1 (en) 2004-07-01
MXPA03008181A (es) 2003-12-12
US8153673B2 (en) 2012-04-10
CN1962641B (zh) 2012-07-04
EP1370534A1 (fr) 2003-12-17
CZ20032500A3 (cs) 2004-02-18
SK10922003A3 (sk) 2004-05-04
WO2002074751A1 (fr) 2002-09-26
US7368465B2 (en) 2008-05-06
HK1060121A1 (en) 2004-07-30
ATE333454T1 (de) 2006-08-15
WO2002074748A1 (fr) 2002-09-26
BR0207984A (pt) 2004-06-15
HUP0400327A3 (en) 2005-06-28
KR100879905B1 (ko) 2009-01-21
US20080171882A1 (en) 2008-07-17
HUP0400202A2 (hu) 2004-08-30
SK287834B6 (sk) 2011-12-05
RU2293729C2 (ru) 2007-02-20
EP1370556B1 (fr) 2006-07-19
IS6946A (is) 2003-09-10
AU2002237632B2 (en) 2007-05-10
NZ528140A (en) 2005-02-25
MY136789A (en) 2008-11-28
RU2003127734A (ru) 2005-03-20
HUP0400194A3 (en) 2004-10-28
NO327114B1 (no) 2009-04-27
NO20034042D0 (no) 2003-09-12
RU2003127735A (ru) 2005-03-20
RU2288228C2 (ru) 2006-11-27
NZ528107A (en) 2005-06-24
US20080306065A1 (en) 2008-12-11
EP1676846A2 (fr) 2006-07-05
JP4390457B2 (ja) 2009-12-24
US20040138276A1 (en) 2004-07-15
CA2440631A1 (fr) 2002-09-26
HK1091492A1 (en) 2007-01-19
DK1370556T3 (da) 2006-10-30
CN1509276A (zh) 2004-06-30
KR20030082987A (ko) 2003-10-23
DE60213216D1 (en) 2006-08-31
JP2004523581A (ja) 2004-08-05
PL205315B1 (pl) 2010-04-30
CN101602731A (zh) 2009-12-16
WO2002074767A8 (fr) 2004-04-22
US20100273849A1 (en) 2010-10-28
US20110003853A1 (en) 2011-01-06
AR035443A1 (es) 2004-05-26
JP2004527515A (ja) 2004-09-09

Similar Documents

Publication Publication Date Title
UA77408C2 (en) Metalloproteinase inhibitors, pharmaceutical composition on its base, and use thereof
UA74624C2 (en) Metalloproteinase inhibitors
AU2002237632A1 (en) Metalloproteinase inhibitors
EP1370536A1 (fr) Inhibiteurs de metalloproteinase
EP1444202B1 (fr) Nouveaux inhibiteurs des metalloproteinases
AU2002237629A1 (en) Metalloproteinase inhibitors